Implication of bevacizumab in fatal arterial thromboembolic incidents

Journal of B.U.ON.

Volumn 14, Issue 1, 2009, Pages 115-117

  Grivas, A A ^a   Trafalis, Dimitrios T ^a,b,c   Athanassiou, A E ^a  

^a METAXA CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NONE   (Greece)

Author keywords

Arterial; Bevacizumab; Cancer; Thromboembolic; VEGF

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; CARBOPLATIN; DACARBAZINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; IFOSFAMIDE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTERY THROMBOSIS; ARTICLE; BONE METASTASIS; CANCER STAGING; CASE REPORT; DRUG FATALITY; FEMALE; HUMAN; LEG DISEASE; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MAXILLA CANCER; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; SPINDLE CELL SARCOMA; THROMBOEMBOLISM; TISSUE NECROSIS;

ADENOCARCINOMA; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXILLARY NEOPLASMS; MIDDLE AGED; SARCOMA; THROMBOEMBOLISM;

EID: 64249088235     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Erman M. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras. J BUON 2007; 12 (Suppl 1): 83-94.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
3. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
4. Vahid B, Marik PE. Pulmonary complications of novel antineo-plastic agents for solid tumors. Chest 2008; 133: 528-538.
5. von Mehren M. New therapeutics for soft-tissue sarcomas in adults. Oncology (Williston Park) 2007; 21: 123-126.
6. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795.
7. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
8. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007; 12: 356-361.
9. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5: 203-220.
10. Ma L, Francia G, Viloria-Petit A et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 2005; 65: 5365-5373.